BTBD1

Across TCGA pan-cancer cohorts, BTBD1 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of BTBD1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where BTBD1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types BTBD1 is over-expressed in tumor, although a few such as KIRC and UCEC show the opposite, repressed pattern.

LIHC, STAD, and CHOL are the cancer types where BTBD1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BTBD1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	All	+0.636	<.001	8	view →
STAD	All	II,III,IV	+0.775	<.001	6	view →
CHOL	All	All	+1.627	<.001	5	view →
HNSC	Female	III,IV	+0.705	.008	3	view →
KIRP	Female	II,III,IV	+0.644	.009	3	view →
KIRC	Male	III,IV	−0.310	.021	3	view →
LUAD	Male	All	+0.283	.007	3	view →
UCEC	All	All	−0.566	.017	2	view →
LUSC	All	All	+0.228	.009	2	view →
BRCA	All	II,III,IV	+0.152	.032	2	view →
BLCA	All	III,IV	+0.319	.039	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

BTBD1–LIHC

Open the LIHC breakdown →